Matching articles for "Trulicity"
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • August 5, 2024; (Issue 1708)
...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
A New Indication for Semaglutide (Wegovy)
The Medical Letter on Drugs and Therapeutics • April 29, 2024; (Issue 1701)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy) has been
approved by the FDA to reduce the risk of major
adverse cardiovascular events (MACE) in adults with
established...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy) has been
approved by the FDA to reduce the risk of major
adverse cardiovascular events (MACE) in adults with
established cardiovascular disease (CVD) and either
obesity or overweight. Semaglutide is the first drug
to be approved for cardiovascular risk reduction in
this population. It is also approved in a lower-dose
injectable formulation as Ozempic and in an oral
formulation as Rybelsus (see Table 1).
In Brief: GI Effects of GLP-1 Receptor Agonists
The Medical Letter on Drugs and Therapeutics • November 27, 2023; (Issue 1690)
Glucagon-like peptide-1 (GLP-1) receptor agonists and
the dual glucose-dependent insulinotropic polypeptide
(GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2...
Glucagon-like peptide-1 (GLP-1) receptor agonists and
the dual glucose-dependent insulinotropic polypeptide
(GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes
and weight management (see Table 1), but they delay
gastric emptying and commonly cause nausea and
vomiting. Gastroparesis and bowel obstruction (ileus)
have also been reported with their use.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 14, 2022; (Issue 1663)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.
Tirzepatide (Mounjaro) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • July 11, 2022; (Issue 1654)
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve...
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes. Tirzepatide, which is injected
subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the
US. Selective GIP receptor agonists are not available
in the US; GLP-1 receptor agonists have been
available for years.
Two New Doses of Dulaglutide (Trulicity) for Diabetes
The Medical Letter on Drugs and Therapeutics • October 19, 2020; (Issue 1609)
The FDA has approved two additional doses (3 mg
and 4.5 mg) of the glucagon-like peptide-1 (GLP-1)
receptor agonist dulaglutide (Trulicity – Lilly) for
treatment of type 2 diabetes in adults. Dulaglutide...
The FDA has approved two additional doses (3 mg
and 4.5 mg) of the glucagon-like peptide-1 (GLP-1)
receptor agonist dulaglutide (Trulicity – Lilly) for
treatment of type 2 diabetes in adults. Dulaglutide has
been available in 0.75- and 1.5-mg doses for years.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 4, 2019; (Issue 1584)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of <7% can prevent
microvascular complications (retinopathy, nephropathy,
and neuropathy), but whether it prevents macrovascular
complications and death is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease (CVD), a history
of severe hypoglycemia, diabetes-related complications,
a limited life expectancy, or a long duration of disease.
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • October 21, 2019; (Issue 1583)
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults....
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • February 25, 2019; (Issue 1566)
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular...
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular complications
in these trials with some sodium-glucose
co-transporter 2 (SGLT2) inhibitors and glucagon-like
peptide 1 (GLP-1) receptor agonists in patients at risk
for cardiovascular disease (see Table 1) have led to
new recommendations.
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 29, 2018; (Issue 1539)
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • August 14, 2017; (Issue 1527)
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of...
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of <7%. Achieving that goal
can prevent microvascular complications (diabetic
retinopathy, nephropathy, neuropathy), but whether it
prevents macrovascular complications (myocardial
infarction [MI], stroke) has been less clear. The FDA
now requires that cardiovascular safety studies be
performed for all new drugs for type 2 diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes have cardiovascular benefits
have led to new interest in the cardiovascular efficacy
and safety of all antidiabetic drugs.
Prescription Drug Prices in the US
The Medical Letter on Drugs and Therapeutics • May 22, 2017; (Issue 1521)
Per capita spending on prescription drugs in the US is
higher than in other industrialized nations,...
Per capita spending on prescription drugs in the US is
higher than in other industrialized nations, including
Canada.
Lixisenatide for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 30, 2017; (Issue 1513)
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in...
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in a
fixed-ratio combination with insulin glargine (Soliqua
100/33). Lixisenatide has been available since 2013 in
many other countries as Lyxumia. It is the fifth GLP-1
receptor agonist to be approved in the US.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 16, 2017; (Issue 1512)
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating...
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating to this target has been shown to
prevent microvascular complications (retinopathy,
nephropathy, and neuropathy), but whether it prevents
macrovascular outcomes is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease, a history of
severe hypoglycemia, diabetes-related complications
or comorbidities, or a long duration of disease.
Two New GLP-1 Receptor Agonists for Diabetes
The Medical Letter on Drugs and Therapeutics • November 10, 2014; (Issue 1455)
Two new injectable GLP-1 (glucagon-like peptide-1)
receptor agonists, dulaglutide (Trulicity [trū li si tee] –
Lilly) and albiglutide (Tanzeum [tan' zee um] – GSK),
have been approved by the FDA for...
Two new injectable GLP-1 (glucagon-like peptide-1)
receptor agonists, dulaglutide (Trulicity [trū li si tee] –
Lilly) and albiglutide (Tanzeum [tan' zee um] – GSK),
have been approved by the FDA for once-weekly
treatment of type 2 diabetes. Other available GLP-1
receptor agonists include exenatide, which is approved
for injection twice daily (Byetta) or once weekly
(Bydureon), and liraglutide (Victoza), which is injected
once daily.